This competing renewal application combines biochemical, molecular genetic and behavioral analyses to probe the mechanism of action of lysergic acid diethylamide (LSD) and other hallucinogenic drugs. In this revision, the most significant modification is the inclusion of new preliminary results that document feasibility and experimental approach. The experimental plan takes advantage of genetically modified mice and new methods of gene transfer for manipulating signal transduction molecules in behaving animals, allowing us to unite our biochemical and behavioral investigations of hallucinogenic drugs and ask questions never before possible. To accomplish this goal, we have established a drug discrimination assay for hallucinogenic drugs in mice; initial studies suggest that the ergot hallucinogen LSD and the hallucinogenic amphetamines have overlapping but distinct stimulus properties; the mechanism is explored in specific aim 1, including possible agonist-directed trafficking of the intracellular signal.
Specific aim 2 utilizes 5-HT2c receptor null mice to test the hypothesis that an absence of the 5-HT2c receptor and its putative antagonism of the 5-HT2A receptor will enhance the cue value of LSD. Preliminary studies in mutant mice support this hypothesis and are bolstered by comparable results using 5-HT2c receptor antagonists in adults. The absence of such pharmacological validation was a major criticism of the previous grant. Our cfos mapping and microinjection experiments have identified the anterior cingulate cortex as an anatomical target for LSD action. We will exploit this finding in Specific Aim 3 by stereotaxically injecting lentiviral vectors encoding proteins that modify intracellular signaling to delineate the signaling pathways that regulate the stimulus properties of hallucinogens. Viral-mediated gene transfer allows the manipulation of signaling pathways in specific brain sites of adult mice, thus avoiding potential developmental or other nonspecific effects in knockout mice. Viral delivery will be linked to genetic manipulation (adult heterozygous Gq mutant mice) to test for synergy between Gq blocking peptide and knockdown of the Gq protein. Explaining the mechanism of action of a powerful hallucinogen such as LSD, which produces profound alterations in cognition, mood, and perception, may lead to a better understanding of why people abuse these drugs and how these processes go awry in mental diseases, such as schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005181-19
Application #
7479825
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Frankenheim, Jerry
Project Start
1988-03-01
Project End
2010-01-31
Budget Start
2008-08-01
Budget End
2010-01-31
Support Year
19
Fiscal Year
2008
Total Cost
$245,546
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Canal, Clinton E; Olaghere da Silva, Uade B; Gresch, Paul J et al. (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209:163-74
Benneyworth, Michael A; Smith, Randy L; Sanders-Bush, Elaine (2008) Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology 33:2206-16
Garcia, Efrain E; Smith, Randy L; Sanders-Bush, Elaine (2007) Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. Neuropharmacology 52:1671-7
Gresch, P J; Strickland, L V; Sanders-Bush, E (2002) Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114:707-13
Grotewiel, M S; Chu, H; Sanders-Bush, E (1994) m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 271:1122-6
Barker, E L; Sanders-Bush, E (1993) 5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. Mol Pharmacol 44:725-30
Burris, K D; Sanders-Bush, E (1992) Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide. Mol Pharmacol 42:826-30
Burris, K D; Breeding, M; Sanders-Bush, E (1991) (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 258:891-6
Barker, E L; Burris, K D; Sanders-Bush, E (1991) Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus. Brain Res 552:330-2
Sanders-Bush, E; Breeding, M (1991) Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs. Psychopharmacology (Berl) 105:340-6

Showing the most recent 10 out of 15 publications